NCT04330599

Brief Summary

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:

  1. 1.To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
  2. 2.To characterise the natural history of COVID-19 in the UK population
  3. 3.To evaluate the impact of COVID-19 on the physical and mental health of the UK population
  4. 4.To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
13,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 1, 2020

Completed
26 days until next milestone

Study Start

First participant enrolled

April 27, 2020

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 27, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2026

Completed
Last Updated

June 8, 2025

Status Verified

June 1, 2025

Enrollment Period

6 years

First QC Date

March 31, 2020

Last Update Submit

June 6, 2025

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

  • Incidence of confirmed COVID-19

    5 years

Secondary Outcomes (14)

  • Incidence of probable or suspected COVID-19

    5 years

  • Incidence of COVID-19 requiring hospitalisation

    5 years

  • Incidence of COVID-19 requiring ventilatory support

    5 years

  • Incidence of fatal COVID-19

    5 years

  • Symptom duration per COVID-19 episode

    5 years

  • +9 more secondary outcomes

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

UK residents aged 16 years or more

You may qualify if:

  • UK resident
  • Age ≥16 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen Mary University of London

London, County (optional), E1 2AB, United Kingdom

RECRUITING

Related Publications (5)

  • Vivaldi G, Talaei M, Blaikley J, Jackson C, Pfeffer PE, Shaheen SO, Martineau AR. Bidirectional relationship between sleep problems and long COVID: a longitudinal analysis of data from the COVIDENCE UK study. BMJ Open Respir Res. 2025 Jun 15;12(1):e002506. doi: 10.1136/bmjresp-2024-002506.

    PMID: 40518292DERIVED

  • Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO, Martineau AR. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023 Oct 6;65:102251. doi: 10.1016/j.eclinm.2023.102251. eCollection 2023 Nov.

    PMID: 38106559DERIVED

  • Tydeman F, Pfeffer PE, Vivaldi G, Holt H, Talaei M, Jolliffe D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Shaheen SO, Martineau AR. Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK). Thorax. 2023 Aug;78(8):752-759. doi: 10.1136/thorax-2022-219591. Epub 2022 Nov 23.

    PMID: 36423925DERIVED

  • Williamson AE, Tydeman F, Miners A, Pyper K, Martineau AR. Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK). BMJ Open. 2022 Aug 23;12(8):e065083. doi: 10.1136/bmjopen-2022-065083.

    PMID: 35998959DERIVED

  • Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, Young KS, Davies MR, Thompson KN, Ashman J, Rajpoot SS, Kayyale AA, El Rifai S, Lloyd PJ, Jolliffe D, Timmis O, Finer S, Iliodromiti S, Miners A, Hopkinson NS, Alam B, Lloyd-Jones G, Dietrich T, Chapple I, Pfeffer PE, McCoy D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Breen G, Shaheen SO, Martineau AR. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax. 2022 Sep;77(9):900-912. doi: 10.1136/thoraxjnl-2021-217487. Epub 2021 Nov 30.

    PMID: 34848555DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

Eluates from dried blood spots

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Adrian Martineau, PhD

CONTACT

+442078822551a.martineau@qmul.ac.uk

Hayley Holt, MSc

CONTACT

h.holt@qmul.ac.uk

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2020

First Posted

April 1, 2020

Study Start

April 27, 2020

Primary Completion

April 27, 2026

Study Completion

April 27, 2026

Last Updated

June 8, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Locations

GB(1)